MARKET

XOMA

XOMA

XOMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

24.49
-0.30
-1.21%
Closed 16:00 09/24 EDT
OPEN
24.59
PREV CLOSE
24.79
HIGH
24.79
LOW
24.01
VOLUME
12.35K
TURNOVER
--
52 WEEK HIGH
46.32
52 WEEK LOW
18.04
MARKET CAP
277.01M
P/E (TTM)
145.41
1D
5D
1M
3M
1Y
5Y
XOMA to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
XOMA Corporation (NASDAQ: XOMA)'s Chief Executive Officer, Jim Neal, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 28, 2021, at 10:20 AM PT.
GlobeNewswire · 4d ago
Here's What XOMA Corporation's (NASDAQ:XOMA) Shareholder Ownership Structure Looks Like
A look at the shareholders of XOMA Corporation ( NASDAQ:XOMA ) can tell us which group is most powerful. Generally...
Simply Wall St. · 5d ago
XOMA to Present at H.C. Wainwright 23rd Annual Global Investment Conference
EMERYVILLE, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference held on September 13-15, 2021...
GlobeNewswire · 09/13 11:30
Avoid These 3 Biotech Stocks That Were Recently Downgraded
StockNews.com · 09/13 11:18
Aegis Capital Maintains Buy on XOMA, Lowers Price Target to $56
Aegis Capital analyst Nathan Weinstein maintains XOMA (NASDAQ:XOMA) with a Buy and lowers the price target from $60 to $56.
Benzinga · 09/09 16:25
--Aegis Capital Adjusts XOMA Price Target to $56 From $60, Maintains Buy Rating
MT Newswires · 09/09 13:40
XOMA's Return On Capital Employed Overview
According to Benzinga Pro data, during Q2, XOMA (NASDAQ:XOMA) posted sales of $901.00 thousand. Earnings were up 52.33%, but XOMA still reported an overall loss of $3.06 million.
Benzinga · 09/08 14:36
Why Did Wedbush Downgrade Xoma?
Benzinga · 09/07 17:49
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XOMA. Analyze the recent business situations of XOMA through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XOMA stock price target is 44.67 with a high estimate of 56.00 and a low estimate of 22.00.
EPS
Institutional Holdings
Institutions: 80
Institutional Holdings: 6.78M
% Owned: 59.98%
Shares Outstanding: 11.31M
TypeInstitutionsShares
Increased
16
124.73K
New
4
24.75K
Decreased
17
143.44K
Sold Out
12
89.06K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
W. Denman Van Ness
Chief Executive Officer/Director
James Neal
Chief Financial Officer/Senior Vice President
Thomas Burns
Independent Director
Heather Franklin
Independent Director
Natasha Hernday
Independent Director
Barbara Kosacz
Independent Director
Joseph Limber
Independent Director
Matthew Perry
Independent Director
Jack Wyszomierski
No Data
About XOMA
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.

Webull offers kinds of XOMA Corp stock information, including NASDAQ:XOMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XOMA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XOMA stock methods without spending real money on the virtual paper trading platform.